Investigating the Role of Celecoxib as a Chemopreventive and Chemotherapeutic Agent for Breast Cancer
Abstract
Although I obtained some interesting data from the experiments outlined in Year 1 of my original statement of work, my statement of work for Year 2 was revised and accepted on 12/10/04. The rationale for my proposed change was based on the recent announcement by Merck and Co. that they have pulled their COX-2 inhibitor rofecoxib off of the market due to unreasonable risks for heart attack and stroke. For my experiments, I had been working with celecoxib, a sister compound of rofecoxib, and several experts in the field fear as if long-term celecoxib administration may also pose a risk to the health of patients. Due to this unexpected announcement, I felt as if the work outlined in my Year 2 statement of work may not be clinically relevant. For Year 2 of my proposal, instead of extending my results with celecoxib, I focused my research on the role of another insulin-like growth factor binding, namely IGFBP-2, in breast cancer. We have obtained from the laboratory of Dr. Martin Gleave (University of British Columbia) the MDA-MB-231 breast cancer cell line transfected with a lentiviral vector expressing IGFBP-2 (231/BP-2), as well as a mock transfected MDA-MB-231 cell line (231/mock). We have determined that the 231/mock cells do not express any IGFBP-2 protein, whereas the 23 1/BP-2 cells express large amounts. Interestingly, we have observed that the 23 1/BP-2 cell line proliferates significantly faster than the 231 /mock cells. Therefore, my results obtained in Year 2 focused on determining the mechanism of the growth promoting effect of IGFBP-2 in breast cancer cells.
Document Details
- Document Type
- Technical Report
- Publication Date
- May 01, 2005
- Accession Number
- ADA437722
Entities
People
- Randy J. Levitt
Organizations
- Jewish General Hospital